STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 14, 2026, 06:56 AM

Cypherpunk Q1 Net Loss $(77.17)M on Digital Asset Fair Value Change

AI Summary

Cypherpunk Technologies Inc. reported a net loss of $(77.17) million for the first quarter of 2026, significantly wider than the $(15.44) million loss in Q1 2025, primarily due to a $(77.56) million unrealized loss on the fair value of its digital asset derivative. The company's digital assets receivable decreased to $73.85 million and cash and cash equivalents fell to $6.69 million as of March 31, 2026. This comes after the company's strategic shift in late 2025 to a digital asset treasury strategy focused on Zcash, alongside winding down most of its biotechnology research and development operations, which led to a substantial reduction in R&D expenses.

Key Highlights

  • Net loss for Q1 2026 was $(77.17) million, compared to $(15.44) million in Q1 2025.
  • Recorded $(77.56) million unrealized loss on fair value of digital asset derivative in Q1 2026.
  • Digital assets receivable decreased to $73.85 million as of March 31, 2026.
  • Cash and cash equivalents fell to $6.69 million as of March 31, 2026.
  • Research and development expenses dropped to $0.16 million in Q1 2026 from $12.91 million in Q1 2025.
  • Total assets decreased to $87.38 million as of March 31, 2026.
  • Issued 8.45 million common shares via ATM sales, raising $5.75 million net.
  • Acquired 303,466.92 ZEC tokens at a weighted average cost of $332.82, totaling $101 million.
CYPH
Biotechnology: Pharmaceutical Preparations
CYPHERPUNK TECHNOLOGIES INC.

Price Impact